Explore 3 Stock Ideas & Industry Insights Download Free Report

Allurion Technologies, Inc.

Company price
0.002 USD 0.00(0%)
Last update at 2026-11-13T14:30:00Z
VOLUME
1300
Market Cap
10.95M

Momentum Score

…

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform offers the Allurion Program, a swallowable and procedure-less intragastric balloon for weight loss, as well as provides access to artificial intelligence-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company operates in Spain, France, Turkey, and internationally. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.23
Low
3.42
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Allurion Technologies develops a non-surgical, single-use gastric balloon and an associated digital weight-management program for treating obesity without endoscopy or anesthesia. It may benefit from rising obesity prevalence, demand for less invasive therapies, international expansion and interest in integrated device-plus-telehealth offerings that could support recurring service revenue and broader adoption.

Key risks include regulatory and safety reviews, significant competition from GLP-1 obesity drugs and surgical or endoscopic alternatives, uncertain reimbursement and commercialization execution, and concentration risk from reliance on a limited product portfolio.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
15.23M
Revenue Per Share
2.02
Gross Profit TTM
9.57M
Debt / Equity
-0.38
ROE
-
Net Debt
23.63M
ROCE
126.50%
Diluted EPS TTM
-3.81

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -28.68M -25.43M -80.34M -37.60M -12.39M
Net income -28.75M -26.15M -82.30M -37.74M -12.39M
Selling general administrative 21.35M 28.40M 46.02M 15.37M 8.82M
Selling and marketing expenses 10.80M 25.93M 46.86M 50.41M 27.14M
Gross profit 9.57M 21.50M 41.50M 50.73M 29.19M
Reconciled depreciation 0.98M 1.00M 1.91M 2.00M 0.71M
Ebit -28.68M -23.17M -69.78M -33.17M -13.06M
Ebitda -27.70M -22.17M -69.03M -32.28M -12.35M
Depreciation and amortization 0.98M 1.00M 0.75M 0.90M 0.71M
Operating income -30.16M -50.20M -79.08M -32.01M -12.50M
Other operating expenses 45.39M 82.31M 132.54M 96.22M 50.74M
Interest expense 0.00M 2.26M 10.57M 4.43M 3.67M
Tax provision 0.07M 0.72M 0.14M 0.14M 0.00M
Net interest income 0.00M -2.26M -9.09M -4.43M -3.67M
Income tax expense 0.07M 0.72M 0.26M 0.14M 3.11M
Total revenue 15.23M 32.11M 53.47M 64.21M 38.24M
Total operating expenses 39.73M 71.70M 120.58M 82.74M 41.69M
Cost of revenue 5.66M 10.61M 11.97M 13.48M 9.05M
Total other income expense net 1.48M 24.77M -1.26M -5.59M 0.12M
Net income from continuing ops -28.75M -26.15M -73.78M -37.74M -12.39M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 15.77M 32.81M 71.71M 51.37M 39.35M
Other current assets 0.76M 1.24M 2.41M 2.49M 1.94M
Total liab 92.96M 110.79M 142.20M 122.81M 73.64M
Total stockholder equity -77.19M -77.98M -70.49M -71.44M -34.28M
Other current liab 6.41M 11.42M 14.59M 15.79M 11.30M
Common stock 0.01M 0.00M 0.01M 0.05M 0.05M
Capital stock 0.01M 0.00M 0.01M 58.05M 58.02M
Retained earnings -250.96M -222.21M -212.80M -132.19M -94.45M
Cash 5.41M 15.38M 38.04M 7.68M 25.84M
Total current liabilities 38.45M 18.86M 65.42M 75.87M 31.61M
Current deferred revenue - - - - 0.20M
Net debt 23.63M 22.54M 3.82M 51.85M 0.30M
Short term debt 28.47M 0.87M 40.46M 54.27M 24.14M
Short long term debt 28.07M - 38.64M 53.36M 24.14M
Short long term debt total 29.04M 37.92M 41.86M 59.53M 26.14M
Other stockholder equity 168.63M 152.60M 143.01M 2.71M 2.14M
Total current assets 12.79M 27.16M 64.82M 43.38M 37.33M
Net receivables 3.95M 7.13M 18.19M 29.35M 6.83M
Long term debt - 35.71M - 3.10M 2.00M
Inventory 2.67M 3.40M 6.17M 3.87M 2.71M
Accounts payable 3.57M 6.57M 10.38M 5.81M 1.62M
Accumulated other comprehensive income 5.14M -8.37M -0.70M - -
Non currrent assets other 0.66M 1.11M 0.12M 2.71M 0.31M
Non current assets total 2.98M 5.66M 6.90M 7.99M 2.02M
Capital lease obligations 0.97M 2.21M 3.21M 3.07M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.61M -1.61M -1.55M -0.91M
Total cashflows from investing activities - -0.61M - - -
Net borrowings 0.00M 0.07M - - -
Total cash from financing activities 18.97M 20.21M 95.99M 30.54M 28.95M
Net income -28.75M -26.15M -80.61M -37.74M -12.39M
Change in cash -9.98M -22.70M 30.40M -17.99M 13.70M
Begin period cash flow 15.72M 38.42M 8.02M 26.02M 12.31M
End period cash flow 5.74M 15.72M 38.42M 8.02M 26.02M
Total cash from operating activities -28.95M -42.30M -63.98M -46.98M -14.33M
Issuance of capital stock 18.97M 21.26M - 0.00M 9.87M
Depreciation 0.98M 1.00M 0.75M 2.00M 0.71M
Dividends paid - - - 0.13M -
Change to inventory -0.49M 0.54M -3.71M -1.15M -1.28M
Change to account receivables 0.84M 8.98M -1.32M -22.82M -0.71M
Sale purchase of stock - - - -776.54M -
Other cashflows from financing activities 18.97M -1.33M 95.92M -0.55M 9.87M
Capital expenditures 0.00M 0.61M 1.61M 1.55M 0.91M
Change in working capital -7.82M 1.60M 0.19M -13.79M -1.27M
Stock based compensation 3.15M 3.06M 8.36M 0.44M 0.31M
Other non cash items 3.50M -21.80M 7.33M 0.84M -2.35M
Free cash flow -28.95M -42.91M -65.59M -48.53M -15.24M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ALUR
Allurion Technologies, Inc.
-
-%
0.00 - 0.83 0.72 - 2.34 -2.15
ABT
Abbott Laboratories
1.27
1.18%
108.52 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC
1.87
1.85%
102.86 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation
-2.75
0.88%
309.64 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG
-0.27
0.55%
48.51 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Allurion Technologies, Inc.

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform offers the Allurion Program, a swallowable and procedure-less intragastric balloon for weight loss, as well as provides access to artificial intelligence-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company operates in Spain, France, Turkey, and internationally. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.

11 Huron Drive, Natick, MA, United States, 01760

508 647 4000

38

Name Title Year Born
Dr. Shantanu K. Gaur M.D. Co-Founder, CEO, President, Principal Financial & Accounting Officer and Director 1986
Dr. Samuel G. Levy Co-Founder 1983
Dr. Ram Chuttani M.D. MD, Chief Medical Officer & Founding Partner 1961
Mr. Ojas A. Buch Chief Operating Officer 1973
Mr. Brendan Michael Gibbons J.D. Chief Legal Officer & Corporate Secretary 1976
Mr. Matt Wright Vice President of People NA
Ms. Joyce Johnson Senior Vice President of Regulatory Affairs & Quality Assurance NA
Dr. Shantanu K. Gaur M.D. Co-Founder, CEO, President, Principal Financial & Accounting Officer and Director 1987
Mr. Ojas A. Buch Chief Operating Officer 1974
Mr. Brendan Michael Gibbons J.D. Chief Legal & People Officer and Secretary 1976

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…